BACKGROUND: We aimed to predict disease-free survival (DFS) in patients who failed to achieve a pathologic complete remission (pCR) after preoperative chemotherapy (PC). PATIENTS AND METHODS: Data from 577 patients treated with PC and operated at the European Institute of Oncology (EIO) were used to develop a nomogram using Cox proportional hazards regression model based on both categorical (pT, positive nodes, human epidermal growth factor receptor 2 (HER2) status, vascular invasion) and continuous histological variables (estrogen receptors and Ki-67 expression) at surgery. The nomogram was tested on a second patient cohort (343 patients) treated in other institutions and subsequently operated at the EIO. RESULTS: The nomogram for DFS based on both categorical and continuous variables had good discrimination in the training and the validation sets (concordance indices 0.73, 0.67). CONCLUSION: The use of a nomogram based on the degree of selected histopathological variables can predict DFS and might help in the adjuvant therapeutic algorithm design.
BACKGROUND: We aimed to predict disease-free survival (DFS) in patients who failed to achieve a pathologic complete remission (pCR) after preoperative chemotherapy (PC). PATIENTS AND METHODS: Data from 577 patients treated with PC and operated at the European Institute of Oncology (EIO) were used to develop a nomogram using Cox proportional hazards regression model based on both categorical (pT, positive nodes, human epidermal growth factor receptor 2 (HER2) status, vascular invasion) and continuous histological variables (estrogen receptors and Ki-67 expression) at surgery. The nomogram was tested on a second patient cohort (343 patients) treated in other institutions and subsequently operated at the EIO. RESULTS: The nomogram for DFS based on both categorical and continuous variables had good discrimination in the training and the validation sets (concordance indices 0.73, 0.67). CONCLUSION: The use of a nomogram based on the degree of selected histopathological variables can predict DFS and might help in the adjuvant therapeutic algorithm design.
Authors: Marco Galvez; Carlos A Castaneda; Joselyn Sanchez; Miluska Castillo; Lia Pamela Rebaza; Gabriela Calderon; Miguel De La Cruz; Jose Manuel Cotrina; Julio Abugattas; Jorge Dunstan; Henry Guerra; Omar Mejia; Henry L Gomez Journal: World J Clin Oncol Date: 2018-04-10
Authors: Silvia Dellapasqua; Vincenzo Bagnardi; Meredith M Regan; Nicole Rotmensz; Mauro G Mastropasqua; Giuseppe Viale; Eugenio Maiorano; Karen N Price; Richard D Gelber; Monica Castiglione-Gertsch; Aron Goldhirsch; Marco Colleoni Journal: Breast Date: 2012-06-29 Impact factor: 4.380
Authors: A Sánchez-Muñoz; Y Plata-Fernández; M Fernández; A Jaén-Morago; M Fernández-Navarro; C de la Torre-Cabrera; C Ramirez-Tortosa; J Pascual; E Alba; P Sánchez-Rovira Journal: Clin Transl Oncol Date: 2013-10-02 Impact factor: 3.405
Authors: Quing Zhu; Liqun Wang; Susan Tannenbaum; Andrew Ricci; Patricia DeFusco; Poornima Hegde Journal: Breast Cancer Res Date: 2014-10-28 Impact factor: 6.466
Authors: Se Hyun Kim; Kyung Hae Jung; Tae-Yong Kim; Seock-Ah Im; In Sil Choi; Yee Soo Chae; Sun Kyung Baek; Seok Yun Kang; Sarah Park; In Hae Park; Keun Seok Lee; Yoon Ji Choi; Soohyeon Lee; Joo Hyuk Sohn; Yeon-Hee Park; Young-Hyuck Im; Jin-Hee Ahn; Sung-Bae Kim; Jee Hyun Kim Journal: Cancer Res Treat Date: 2016-03-23 Impact factor: 4.679